- April 26, 2022
- Newsletter
- 617-430-5616
Menu
» Home » CAD » Oncology » Genito-Urinary » Endometrial Carcinoma
ADVERTISEMENT
ADVERTISEMENT
» Home » CAD » Oncology » Genito-Urinary » Endometrial Carcinoma
Background
Epidemiology
Anatomy
Pathophysiology
Etiology
Genetics
Prognostic Factors
Clinical History
Physical Examination
Age group
Associated comorbidity
Associated activity
Acuity of presentation
Differential Diagnoses
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
by Stage
by Modality
Chemotherapy
Radiation Therapy
Surgical Interventions
Hormone Therapy
Immunotherapy
Hyperthermia
Photodynamic Therapy
Stem Cell Transplant
Targeted Therapy
Palliative Care
Medication
1
mg
Orally
once a day
depending upon symptoms
3.6 mg subcutaneously placed in the upper abdominal wall for every 28days The maximum duration of the treatment is six months
20
mg
Orally
4 times a day
It is given in combination with 200 mg of intravenous pembrolizumab every 3 weeks
Advanced cancer:
:
Initial dose for cycle 1: 8 mg/kg IV over 90 mins
Maintenance dose: 6 mg/kg IV infused over 30 to 90 minutes every 3 Weeks in combination with carboplatin and paclitaxel for 6 cycles
Gastric metastatic cancer:
Initial dose for cycle 1: 8 mg/kg IV over 90 mins
Maintenance dose: 6 mg/kg IV infused over 30 to 90 minutes every 3 Weeks in combination with cisplatin and capecitabine/fluorouracil for 6 cycles
Mild condition: 200-400 mg/day orally divided twice daily
Moderate to severe condition: 800 mg/day orally divided twice daily
Decrease the dose accordingly to sustain amenorrhea
Continue the therapy ranging from 6-9 months
Indicated for reducing the pain and symptoms due to advanced endometrial carcinoma
40-320 mg orally each day in divided doses
Check on the efficacy 2 months post-treatment
A maximum dose of up to 800 mg/day can be utilized
It shouldn’t be used as a substitute for radiotherapy, chemotherapy, or surgery
Indicated for Metastatic Endometrial Carcinoma
Depo-Provera is only indicated for relieving the symptoms of recurrent, metastatic, or inoperable endometrial carcinoma
Initially 400-1000 mg intramuscularly each week
For the Initial dose
Dose 1 to Dose 4-Intravenous infusion of 500 mg for 30 minutes, repeated every three weeks
For the Maintenance dose
Starting from 3 weeks after Dose 4 (Dose 5 onwards)- Intravenous infusion of 1000 mg for 30 minutes, given for six weeks
Future Trends
References
ADVERTISEMENT
» Home » CAD » Oncology » Genito-Urinary » Endometrial Carcinoma
1
mg
Orally
once a day
depending upon symptoms
3.6 mg subcutaneously placed in the upper abdominal wall for every 28days The maximum duration of the treatment is six months
20
mg
Orally
4 times a day
It is given in combination with 200 mg of intravenous pembrolizumab every 3 weeks
Advanced cancer:
:
Initial dose for cycle 1: 8 mg/kg IV over 90 mins
Maintenance dose: 6 mg/kg IV infused over 30 to 90 minutes every 3 Weeks in combination with carboplatin and paclitaxel for 6 cycles
Gastric metastatic cancer:
Initial dose for cycle 1: 8 mg/kg IV over 90 mins
Maintenance dose: 6 mg/kg IV infused over 30 to 90 minutes every 3 Weeks in combination with cisplatin and capecitabine/fluorouracil for 6 cycles
Mild condition: 200-400 mg/day orally divided twice daily
Moderate to severe condition: 800 mg/day orally divided twice daily
Decrease the dose accordingly to sustain amenorrhea
Continue the therapy ranging from 6-9 months
Indicated for reducing the pain and symptoms due to advanced endometrial carcinoma
40-320 mg orally each day in divided doses
Check on the efficacy 2 months post-treatment
A maximum dose of up to 800 mg/day can be utilized
It shouldn’t be used as a substitute for radiotherapy, chemotherapy, or surgery
Indicated for Metastatic Endometrial Carcinoma
Depo-Provera is only indicated for relieving the symptoms of recurrent, metastatic, or inoperable endometrial carcinoma
Initially 400-1000 mg intramuscularly each week
For the Initial dose
Dose 1 to Dose 4-Intravenous infusion of 500 mg for 30 minutes, repeated every three weeks
For the Maintenance dose
Starting from 3 weeks after Dose 4 (Dose 5 onwards)- Intravenous infusion of 1000 mg for 30 minutes, given for six weeks
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.